-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hutchison Whampoa has launched a Global Phase III Trial (FRESCO-2 Study) in the United States, Europe and Japan to assess the effectiveness and safety of Fruquintinib's treatment of metastatic colorectal cancer (CRC), the first of which was taken in the United States on September 3, 2020.
FRESCO-2 is a randomized, double-blind, placebo-controlled multi-center trial for patients with metastasis CRC.
the main endpoint of the study was the overall survival rate (OS).
phase III trial will be conducted in approximately 130 locations in 10 countries.
June 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track eligibility for Fruquintinib therapeutic metastasis CRC.
FRESCO-2 research design has also been reviewed and approved by the European Medicines Agency (EMA) and the Japan Pharmaceutical and Medical Devices Agency (PMDA).
Fruquintinib is a highly selective oral inhibitor of vascular endostroin growth factor (VEGFR) 1/2/3.
VEGFR inhibitors play a key role in blocking angiogenesics in tumors.
Fruquintinib is designed to improve kinase selectivity to minimize off-target toxicity.
to date, patients treated with Fruquintinib have generally had good tolerance, and according to preclinical assessment, Fruquintinib has no significant drug interaction, indicating that it is suitable for use in combination with other anticancer therapies.
.